Stock markets have rallied after U.S. President Donald Trump announced a ceasefire in the Israel-Iran conflict, although the ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Hims & Hers Health Inc. (HIMS) rebounded 4.38% in after-hours trading Monday, partially clawing back losses after the stock ...

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...

The endocrinologist and researcher was one of several investigators who presented Phase 3 clinical trial results at the 85th Scientific Sessions of the American Diabetes Association for a long-lasting ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance coverage ...

The calming in the oil market came as several analysts said Iran would likely refrain from closing the waterway. Iran itself ...

Hims & Hers Health Inc.'s stock booked record losses Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with the telehealth ...

U.S. stocks are drifting, and oil prices are flip-flopping following the United States’ bunker-busting entry into Israel’s ...

Trump’s tariffs and the trade war continue to affect global markets as the Israel-Iran conflict unfolds. Follow along for live updates on the Dow, S&P 500 and Nasdaq.

U.S. pharma companies should pay rather more of their corporate income tax in the U.S.—and start producing more of their best drugs in the U.S. as well.

Semaglutide improved time spent in glycemic range, time below rate and reduced body weight with low rates of hypoglycemia ...